These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases. Lorenz EC; Lieske JC; Seide BM; Olson JB; Mehta R; Milliner DS Am J Kidney Dis; 2021 May; 77(5):816-819. PubMed ID: 32891627 [TBL] [Abstract][Full Text] [Related]
69. Transplantation for Primary Hyperoxaluria Type 1: Designing New Strategies in the Era of Promising Therapeutic Perspectives. Devresse A; Cochat P; Godefroid N; Kanaan N Kidney Int Rep; 2020 Dec; 5(12):2136-2145. PubMed ID: 33305106 [TBL] [Abstract][Full Text] [Related]
73. A randomised Phase I/II trial to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Hoppe B; Niaudet P; Salomon R; Harambat J; Hulton SA; Van't Hoff W; Moochhala SH; Deschênes G; Lindner E; Sjögren A; Cochat P Pediatr Nephrol; 2017 May; 32(5):781-790. PubMed ID: 27924398 [TBL] [Abstract][Full Text] [Related]
74. Infant primary hyperoxaluria type 1 Zheng Y; Li Q; Liang S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Jun; 49(6):856-862. PubMed ID: 39311781 [TBL] [Abstract][Full Text] [Related]
75. Monogenic features of urolithiasis: A comprehensive review. Koo KC; Halawani A; Wong VKF; Lange D; Chew BH Asian J Urol; 2024 Apr; 11(2):169-179. PubMed ID: 38680588 [TBL] [Abstract][Full Text] [Related]
76. Primary hyperoxaluria type 1 in children: clinical and laboratory manifestations and outcome. Wannous H Pediatr Nephrol; 2023 Aug; 38(8):2643-2648. PubMed ID: 36917293 [TBL] [Abstract][Full Text] [Related]
77. Effect of liver transplantation with primary hyperoxaluria type 1: Five case reports and review of literature. Wang XY; Zeng ZG; Zhu ZJ; Wei L; Qu W; Liu Y; Tan YL; Wang J; Zhang HM; Shi W; Sun LY World J Clin Cases; 2023 Feb; 11(5):1068-1076. PubMed ID: 36874433 [TBL] [Abstract][Full Text] [Related]
78. Searching glycolate oxidase inhibitors based on QSAR, molecular docking, and molecular dynamic simulation approaches. Cabrera N; Cuesta SA; Mora JR; Paz JL; Márquez EA; Espinoza-Montero PJ; Marrero-Ponce Y; Pérez N; Contreras-Torres E Sci Rep; 2022 Nov; 12(1):19969. PubMed ID: 36402831 [TBL] [Abstract][Full Text] [Related]